Clinical Trial Search

Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Continuous Complete Remission at 1 Year — 21 participants

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg

Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability

Primary: Complete Response Rate — 89 percentage of patients

Primary: Disease Free Survival — 1.7 years

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants With Complete Remission (CR) — 68 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: Complete Remission — 10 participants

Primary: Complete Remission — 52 percentage of participants

Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants

Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants

Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Fat Mass — 5.1; 10.7 percent change in fat mass

Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs

Primary: Overall Survival at One Year — 19 Participants

Primary: Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy — 91 percentage of analyzable subjects